Indevr
Boulder, US · Delaware corporation · 1 known investors
InDevR develops off-the-shelf and custom analytical testing solutions, including its VaxArray microarray platform and multiplex immunoassays, for the development, optimization, and manufacturing of mRNA-, protein-, polysaccharide, conjugate, and viral vector-based vaccines. It serves vaccine developers and manufacturers with GMP- and 21 CFR Part 11-compliant assays used across R&D, clinical trials, and release testing.
Founders & leadership
KR
Kathy RowlenCo-founder, Scientific Advisor (former CEO)
SR
Shannon RodriguezChief Operations Officer
ED
Erica DawsonChief Technical Officer
CH
Craig HoechstetterChief Commercial Officer
MC
Michael ChangNamed on SEC filing
LK
Laura KuckNamed on SEC filing
Board
GR
Investors · 1
Reported raises · per SEC filings
Form D private placements$10M disclosed across 2 rounds · 2019–2022
▶$6MraisedJan 2023 · 3 investors · BiotechnologyRule 506(b)
▶$6MraisedJan 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ChangDirector
- Shannon RodriguezExecutive Officer, Director, Promoter
- Kathy RowlenExecutive Officer, Director, Promoter
- Michael ReynierDirector
- Erica DawsonExecutive Officer
- Offering amount
- $9M
- Amount sold
- $6M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ChangDirector
- Kathy RowlenExecutive Officer, Director, Promoter
- Shannon RodriguezExecutive Officer, Director, Promoter
- Laura KuckExecutive Officer
- Erica DawsonExecutive Officer
- Glenn RockmanDirector
- Offering amount
- $7M
- Amount sold
- $4M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Indevr do?
- InDevR develops off-the-shelf and custom analytical testing solutions, including its VaxArray microarray platform and multiplex immunoassays, for the development, optimization, and manufacturing of mRNA-, protein-, polysaccharide, conjugate, and viral vector-based vaccines. It serves vaccine developers and manufacturers with GMP- and 21 CFR Part 11-compliant assays used across R&D, clinical trials, and release testing.
- Who founded Indevr?
- Indevr was founded by Kathy Rowlen.
- Who are Indevr's investors?
- Indevr's investors include Adjuvant Capital.
- How much funding has Indevr raised?
- Indevr has disclosed $10M raised across 2 rounds.
- Where is Indevr headquartered?
- Indevr is headquartered in Boulder, US.